Information Journal Paper
APA:
Copy. (2020). Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 55(5), 0-0. SID. https://sid.ir/paper/702063/en
Vancouver:
Copy. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS[Internet]. 2020;55(5):0-0. Available from: https://sid.ir/paper/702063/en
IEEE:
Copy, “Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality,” INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 55, no. 5, pp. 0–0, 2020, [Online]. Available: https://sid.ir/paper/702063/en